Bourdette DN, Edmonds, E, Smith C, Bowen JD, Guttmann CRG, Nagy ZP, Simon J, Whitham R, Lovera J, Yadav V, Mass M, Spencer L, Culbertson N, Bartholomew RM, Theofan G, Milano J, Offner H, Vandenbark AA. A highly immunogenic trivalent T cell receptor peptide vaccine. Multiple Sclerosis 11: 1-10, 2005. [PubMed] [Reprint]

Bunde T, Kirchner A, Hoffmeister B, Habedank D, Hetzer R, Cherepnev G, Proesch S, Reinke P, Volk H-D, Lehmkuhl H, Kern F. Protection from cytomegalovirus after transplantation is orrelated with immediate early 1–specific CD8 T cells. J Exp Med 201: 1031–1036, 2005. [PubMed] [Reprint]

Danke NA, Koelle DM, Kwok WW. Persistence of herpes simplex virus type 2 VP16-specific CD4(+) T cells. Hum Immunol 66: 777-87, 2005. [PubMed] [Reprint]

Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 3: 454-64, 2005. [PubMed] [Reprint]

Giannoni F, Barnett J, Bi K, Samodal R, Lanza P, Marchese P, Billetta R, Vita R, Klein MR, Prakken B, Kwok WW, Sercarz E, Altman A, Albani S. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C theta translocation to the T cell plasma membrane. J Immunol 174: 3204-11, 2005. [PubMed] [Reprint]

Gonzalez JC, Kwok WW, Wald A, McClurkan CL, Huang J, Koelle DM. Expression of cutaneous lymphocyte-associated antigen and E-selectin ligand by circulating human memory CD4+ T lymphocytes specific for herpes simplex virus type 2. J Infect Dis 191: 243-54, 2005. [PubMed] [Reprint]

Hernandez-Fuentes MP, Lechler RI. Chronic graft loss: Immunological and non-immunological factors. In "Kidney Transplantation: Strategies to Prevent Organ Rejection. Ronco C., Chiaramonte S., Remuzzi G (eds). Contrib Nephrol, Basel , Karger, 146: 54-64, 2005. [PubMed]

Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA. Decreased Foxp3 levels in multiple sclerosis patients. J Neurosci Res 81: 45-52, 2005. [PubMed] [Reprint]

Mallone R, Kochik SA, Reijonen H, Carson B, Ziegler SF, Kwok W, Nepom GT. Functional avidity directs T-cell fate in autoreactive CD4+ T-cells. Blood 102: 4103-8, 2005. [PubMed] [Reprint]

Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M. Messenger RNA for FOXP3 in the urine of renal allograft recipients. New Engl J Med 353: 2342-51, 2005. [PubMed] [Reprint]

Offner H, Vandenbark AA. Congruent effects of estrogen and T cell receptor peptide therapy on regulatory T cells in EAE and MS. Intl Rev Immunol 24:447-477, 2005.

Vandenbark AA. TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells. Current Drug Targets – Inflammation & Allergy 4: 217-229, 2005. [PubMed]

Abstracts

Asare AL, Kolchinsky SA, Wood P, Seyfert-Margolis VL. Comparison of RNA Preparation Methods and Their Effect on Cytokine/Chemokine Gene Expression (Abstract Su1.60). 2005 Meeting of the Federation of Clinical Immunology Societies, Boston , MA , May 12-16, 2005. [Abstract]

Carreno MR, Ciancio G, Burke GW, Cirocco R, Salman F, Mathew J, Jin Y, Miller J, Esquenazi, V. Precursor dendritic cell subsets in kidney allograft recipients after induction with alemtuzumab (C1H) vs Thymoglobulin (Thy) vs Daclizumab (Dac) vs a C1H recipient given donor specific stem cells (DHSC). ASHI 31st Annual Meeting, Washington , DC , October 17-21, 2005. [Abstract]

Carreno M, Cirocco R, Mathew J, Ciancio G, Burke GW, Miller J, Esquenazi V. T regulatory cells after induction therapy with Campath-1H, vs Thymoglobulin vs Daclizumab in kidney transplant recipients. American Transplant Congress, Seattle Washington, May 21, 2005. [Abstract]

Casale, T.B., Kline, J.N., Busse, W.W., Ballas, Z.K., Mokhtarani, M., Seyfert-Margolis, V., Bateman, K., Moss, M.H., Townley, R.G.: Omalizumab pretreatment prevents allergic reactions due to rush immunotherapy (RIT) [Abstract 259]. J Allergy Clin Immunol 115(2): S65. 2005 AAAAI Annual Meeting, San Antonio , TX , March 8-22, 2005. [Abstract]

Cirocco R, Careno M, Mathew J, Valone T, Esquenazi V, Miller J. Increased production of the regulatory T-cell transcription factor Fox P-3m-RNA and CD4+CD25+ cells in Campath-1H and donor hematopoetic stem cell treated kidney transplant recipients. ASHI 31st Annual Meeting, Washington , DC , October 17-21, 2005. [Abstract]

Collin F, Asare AL, Kolchinsky SA, Speed TP, Seyfert-Margolis VL. NUSE and RLE: Quality assessment of oligonucleotide microarray data to quantify systemic variation (Abstract Su2.110). 2005 Meeting of the Federation of Clinical Immunology Societies, Boston , MA , May 12-16, 2005. [Abstract]

Cornell LD, Della Pelle P, Brousiadies N, Collins AB , Colvin RB: Endothelial response to rejection: Enhanced expression of complement regulatory proteins decay accelerating factor (DAF, CD55) and protectin (CD59) in human renal allografts. Mod Pathol 17: 285A, 2004.

Garcia-Morales RO, Esquenazi V, Kleiner G, Cirocco RE, Burke GW, Carreno MR, Ciancio G, Kenyon NS, Ricordi C, Tzakis AG, Shariatmadar S, Miller J. Comparative chimerism levels in cadaver and living related donor whole bone marrow infused kidney recipients vs. a 2X stem cell-infused recipient treated with alemtuzumab. 9th Basic Science Symposium of the International Transplantation Society, La Baule , France , June 19-23, 2005. [Abstract]

Hernandez-Fuentes MP, Sagoo P, Jimenez E, Rovis F, Stevenson S, Warrens A, Lechler R. Immune Monitoring in Renal Transplantation. British Society of Immunology, Harrogate, UK. December 2005. [Abstract]

Kawai T, Sachs DH, Spitzer T, Tolkoff-Rubin N, Delmonico F, Saidman S, Shaffer J, Williams W, Dey B, McAfee S, Ko D, Hertl M, Goes N, Wong W, Fishman JA, Colvin RB, Sykes M, Cosimi B. Combined kidney and bone marrow transplantation for induction of mixed chimerism and renal allograft tolerance in HLA matched and mismatched recipients [Abstract 1535]. 2005 American Transplant Congress, Seattle , WA , May 2005. [Abstract]

Khoury SJ, Viglietta V, Buckle G, Hafler D, Bourcier K, Guttmann C, Bikowski M, Rusche J, Landy H, McNally J, Jauregui K. A Phase I Trial of CTLA4Ig Treatment in MS. [Abstract S46.004] 57th Annual Meeting of the American Academy of Neurology, Miami Beach, Florida, April 9-15, 2005. [Abstract]

Kline JN, Casale TB, Busse WW, Ballas ZK,Mokhtarani M, Bromstead C, Seyfert-
Margolis V, Asare A, Bateman K, Moss MH, Townley RG. Omalizumab Plus Rush Immunotherapy (RIT) Is More Effective Than RIT Alone In Preventing Ragweed-Induced Seasonal Allergic Rhinitis (SAR) Symptoms. [Abstract 827]. J Allergy Clin Immunol 115(2); S207. 2005 AAAAI Annual Meeting, San Antonio, TX , March 8-22, 2005. [Abstract]

Klunker S, Francis JN and Durham SR. Ragweed immunotherapy serum inhibits facilitated allergen presentation. 2005 Annual Meeting of the British Society for Allergy & Clinical Immunology, Loughborough, UK , July 18-20, 2005.

Liu WH, Szot G, Earle KE, Herold KC, Masharani U, Gitelman SE, Bluestone JA. Immune monitoring: the effects of hOKT3γ1 (Ala-Ala) in a patient with new onset type 1 diabetes mellitus. (Abstract Su1.70). 2005 Meeting of the Federation of Clinical Immunology Societies, Boston , MA , May 12-16, 2005. [Abstract]

Mathew JM, Vallone T, Carreno M, Rosen A, Gomez C, Garcia-Morales R, Blomberg B, Fuller L, Burke G, Ciancio G, Esquenazi V, Miller J. Regulatory cell development in an LRD-kidney transplant recipient treated with alemtuzumab and donor stem cell infusions (ITN protocol). ASHI 31st Annual Meeting, Washington , DC , October 17-21, 2005. [Abstract]

Offner H, Huan J, Bartholomew R, Bourdette D, and Vandenbark A. Expression of the Treg cell associated Foxp3 gene is decreased in MS patients and increases following immunization with a T cell receptor peptide vaccine. J Neurol 252 (Suppl 2):20, 2005. 15th Meeting of the European Neurological Society, Vienna, Austria, June 18 -22, 2005. [Abstract]

Paraskevopoulos G, Jacobson MR, Carr V, Calderon M, Till SJ, Francis JN, Durham SR. Grass pollen injection immunotherapy: Time course of suppression of allergen-induced late-phase skin responses. J Allergy Clin Immunology. 2005; 115:S266.

Raddassi K, Bourcier K, Estevam J, Hafler DA, Seyfert-Margolis V. Effect of freezing/thawing conditions and their optimization for quality control of PBMC viability and functional assays (Abstract Su1.106). 2005 Meeting of the Federation of Clinical Immunology Societies, Boston, MA, May 12-16, 2005. [Abstract]

Shamji M, Wilcock L, Larché M, Durham S and Francis J. Analytical validation of a novel flow cytometric-based Facilitated Allergen Presentation (FAP) assay as a tool for monitoring allergen-specific immunotherapy. 2005 Annual Meeting of the British Society for Allergy & Clinical Immunology, Loughborough , UK , July 18-20, 2005.

Shankar R, O'Connor M, Martins S, Tu S, Parrish D, Musen M, Das A. A knowledge-driven approach to manage clinical trial protocols in the Immune Tolerance Network. American Medical Informatics Association Symposium, October 25, 2006. [Poster]

Vandenbark A, Huan J, Bartholomew R, Offner H, Bourdette D. Decreased Foxp3 levels in MS patients are normalized by TCR peptide vaccination. 19th National Congress of the Polish Neurological Society, Lodz , Poland , Aug 31 – Sept 3, 2005. [Abstract]

Vandenbark A, Huan J, Bartholomew R, Offner H, Bourdette D. TCR peptide vaccination in MS induces high levels of IL-10 and restores decreased Foxp3 levels. 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS), Thessaloniki, Greece, Sept 28 – Oct 1, 2005. [Abstract]

Wilcock LK, Wachholz PA, Na D H, Klunker S, Francis JN, Larsen JN, Durham SR. Time-course of serum IgG4 levels and IgG inhibitory activity following withdrawal of grass pollen immunotherapy (IT). J Allergy Clin Immunology. 2005; 115:S265.